303 related articles for article (PubMed ID: 35584326)
21. Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation.
Liu BY; Kim YC; Leatherberry V; Cowin P; Alexander CM
Oncogene; 2003 Dec; 22(58):9243-53. PubMed ID: 14681683
[TBL] [Abstract][Full Text] [Related]
22. Syndecan-1 facilitates breast cancer metastasis to the brain.
Sayyad MR; Puchalapalli M; Vergara NG; Wangensteen SM; Moore M; Mu L; Edwards C; Anderson A; Kall S; Sullivan M; Dozmorov M; Singh J; Idowu MO; Koblinski JE
Breast Cancer Res Treat; 2019 Nov; 178(1):35-49. PubMed ID: 31327090
[TBL] [Abstract][Full Text] [Related]
23. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
Nikolova V; Koo CY; Ibrahim SA; Wang Z; Spillmann D; Dreier R; Kelsch R; Fischgräbe J; Smollich M; Rossi LH; Sibrowski W; Wülfing P; Kiesel L; Yip GW; Götte M
Carcinogenesis; 2009 Mar; 30(3):397-407. PubMed ID: 19126645
[TBL] [Abstract][Full Text] [Related]
24. Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis.
Zhang Y; Wang Z; Liu J; Zhang S; Fei J; Li J; Zhang T; Wang J; Park PW; Chen Y
J Cell Mol Med; 2017 Jan; 21(1):13-25. PubMed ID: 27558380
[TBL] [Abstract][Full Text] [Related]
25. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.
Ibrahim SA; Hassan H; Vilardo L; Kumar SK; Kumar AV; Kelsch R; Schneider C; Kiesel L; Eich HT; Zucchi I; Reinbold R; Greve B; Götte M
PLoS One; 2013; 8(12):e85737. PubMed ID: 24392029
[TBL] [Abstract][Full Text] [Related]
26. CD138 (syndecan-1) expression in health and disease.
Palaiologou M; Delladetsima I; Tiniakos D
Histol Histopathol; 2014 Feb; 29(2):177-89. PubMed ID: 24150912
[TBL] [Abstract][Full Text] [Related]
27. Syndecan-1 knockdown inhibits glioma cell proliferation and invasion by deregulating a c-src/FAK-associated signaling pathway.
Shi S; Zhong D; Xiao Y; Wang B; Wang W; Zhang F; Huang H
Oncotarget; 2017 Jun; 8(25):40922-40934. PubMed ID: 28422726
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases.
Miše I; Vučić M
Anal Cell Pathol (Amst); 2018; 2018():9432375. PubMed ID: 30151336
[TBL] [Abstract][Full Text] [Related]
29. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
Szarvas T; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky I; Rübben H
Hum Pathol; 2014 Apr; 45(4):674-82. PubMed ID: 24656090
[TBL] [Abstract][Full Text] [Related]
30. Loss of SDC1 Expression Is Associated with Poor Prognosis of Colorectal Cancer Patients in Northern China.
Li K; Li L; Wu X; Yu J; Ma H; Zhang R; Li Y; Wang W
Dis Markers; 2019; 2019():3768708. PubMed ID: 31182980
[TBL] [Abstract][Full Text] [Related]
31. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes.
Shi Q; Jiang J; Luo G
J Virol; 2013 Jun; 87(12):6866-75. PubMed ID: 23576506
[TBL] [Abstract][Full Text] [Related]
32. Sdc1 negatively modulates carcinoma cell motility and invasion.
Ishikawa T; Kramer RH
Exp Cell Res; 2010 Apr; 316(6):951-65. PubMed ID: 20036233
[TBL] [Abstract][Full Text] [Related]
33. Syndecan-1 and Its Expanding List of Contacts.
Stepp MA; Pal-Ghosh S; Tadvalkar G; Pajoohesh-Ganji A
Adv Wound Care (New Rochelle); 2015 Apr; 4(4):235-249. PubMed ID: 25945286
[No Abstract] [Full Text] [Related]
34. The niche factor syndecan-1 regulates the maintenance and proliferation of neural progenitor cells during mammalian cortical development.
Wang Q; Yang L; Alexander C; Temple S
PLoS One; 2012; 7(8):e42883. PubMed ID: 22936997
[TBL] [Abstract][Full Text] [Related]
35. Soluble syndecan-1 as marker of intestinal inflammation: A preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis.
Floer M; Clausen M; Meister T; Vollenberg R; Bettenworth D; Tepasse PR
Adv Clin Exp Med; 2021 Jul; 30(7):655-660. PubMed ID: 34286513
[TBL] [Abstract][Full Text] [Related]
36. Exosome-delivered syndecan-1 rescues acute lung injury via a FAK/p190RhoGAP/RhoA/ROCK/NF-κB signaling axis and glycocalyx enhancement.
Zhang C; Guo F; Chang M; Zhou Z; Yi L; Gao C; Huang X; Huan J
Exp Cell Res; 2019 Nov; 384(1):111596. PubMed ID: 31487506
[TBL] [Abstract][Full Text] [Related]
37. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
38. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.
Maeda T; Desouky J; Friedl A
Oncogene; 2006 Mar; 25(9):1408-12. PubMed ID: 16247452
[TBL] [Abstract][Full Text] [Related]
39. Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells.
Wang X; He J; Zhao X; Qi T; Zhang T; Kong C
Oncol Rep; 2018 Apr; 39(4):1835-1842. PubMed ID: 29484435
[TBL] [Abstract][Full Text] [Related]
40. Dually modified transmembrane proteoglycans in development and disease.
Jenkins LM; Horst B; Lancaster CL; Mythreye K
Cytokine Growth Factor Rev; 2018 Feb; 39():124-136. PubMed ID: 29291930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
